HealingMaps

By clinical trials Ketamine Articles Psilocybin Articles psychedelics Medicaid is the largest payer for behavioral health in the country. A new report asks what happens when psychedelic-assisted therapy reaches it. The answer is more complicated than approval followed by coverage. It came from the Center for Health Care Strategies and surfaced in Psychedelic Alpha’s September bulletin. Cash pay economics look different the day a payer shows up.

By clinical trials Ketamine Articles ketamine therapy ketamine treatment Someone in your market searches the word psychedelic. Before reaching a single clinic they pass an ad from Johnson & Johnson, two from national at-home ketamine companies, and two for drugs that are not approved. Psychedelic Alpha reported the shift in its September bulletin. Pharma has started buying the category. Paid search is one of the few costs a clinic cannot negotiate down alone.

By clinical trials psilocybin Psilocybin Articles psychedelics A systematic review pulled together every usable study on psilocybin microdosing and found something the enthusiasm has outrun. Two of the eleven studies were placebo controlled. Neither showed a significant improvement. News-Medical summarized the review on September 7. Patients arrive with microdosing questions whether or not a clinic offers it.

By clinical trials pain psilocybin Psilocybin Articles psychedelics Psilocybin given before chemotherapy prevented nerve damage in mice, and it kept working across six consecutive treatment cycles. The finding was published in Science by a team at MD Anderson. The detail that matters most is buried further down. A non-hallucinogenic compound protected the nerves just as well. Chronic pain referrals keep widening faster than most clinics plan for.

By MDMA articles psychedelics In August we reported that MDMA assisted therapy had gone back to the FDA without a new phase 3 trial. The obvious question was who would fund that gamble after the agency rejected the first application. The Wall Street Journal answered it on September 5. A director at SpaceX wrote a 25 million dollar check. Who funds a therapy shapes how fast it arrives and what it costs on the other end.

By clinical trials Psilocybin Articles psychedelics PTSD veterans The American Legion has formally backed psychedelic-assisted therapy for veterans with PTSD and traumatic brain injury. Delegates adopted the resolution at the organization’s 107th National Convention in Louisville, and Military.com reported it on September 8. The interesting part is not the endorsement. It is how specific the asks are. Credentialing standards tend to arrive faster than the approvals that trigger them.

By clinical trials Ketamine Articles ketamine for depression ketamine therapy ketamine treatment Bipolar patients get screened out of ketamine treatment routinely. The reason is a worry about triggering mania. Until now that worry had almost no controlled evidence behind it, in either direction. A Toronto team has now run the trial, and it was published in JAMA Psychiatry on September 2, 2026. Widening who a practice can safely treat is a growth question before it is a clinical one.

By clinical trials Ketamine Articles ketamine therapy ketamine treatment The FDA told a drug developer that two sentences on a conference booth were extremely concerning. The product is an extended release ketamine injection. The venue was the American Psychiatric Association annual meeting. FiercePharma reported the action, and the language the agency objected to is language a lot of ketamine marketing borrows. Marketing review is cheaper than the letter that follows a bad claim.

By clinical trials psilocybin Psilocybin Articles psychedelics A Johns Hopkins pilot found that a high oral dose of THC felt, to its participants, a lot like psilocybin. The paper appeared in Psychopharmacology and moved fast through the psychedelic press, including Marijuana Moment. Before it travels further, the sample size deserves equal billing. Four people took part. Patients arrive having read the headline, not the sample size.

By psilocybin Psilocybin Articles psychedelic research psychedelics Cognitive flexibility is one of the most cited reasons psychedelics are supposed to work. The drug loosens rigid thinking, the argument goes, and the patient can revise beliefs that were stuck. A review in Neuroscience & Biobehavioral Reviews says the evidence does not actually support that as a reliable effect. Sometimes flexibility gets worse. The review is indexed on PubMed.